Meeting
2021 ASCO Annual Meeting
Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.
Authors
Florian Clatot
INSERM U1245, IRON Group, Centre Henri Becquerel, University Hospital, University of Normandy, Rouen, France
Florian Clatot , Kelsey Thomas , Matteo Lambertini , Nathalie Olympios , Orianne Duhamel , Anne Perdrix , Richard Anderson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 552)
DOI
10.1200/JCO.2021.39.15_suppl.552
Abstract #
552
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).
First Author: Jenny Furlanetto
Poster
2021 ASCO Annual Meeting
Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.
First Author: Rob C. Stein
Poster
2017 ASCO Annual Meeting
Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
First Author: Vivianne C. Tjan-Heijnen
First Author: Juerg Bernhard